Registry of Cases of Pulmonary Hypertension in Army Hospitals

Abstract

ulmonary hypertension (PH) is a substantial global health issue. PH is not in itself a diagnosis, but is a haemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure (PAPm) ≥ 25 mmHg at rest as assessed by right heart catheterization (RHC).The is no sufficient data to support the definition of Pulmonary hypertension on exercise.(1) The term PAH describes a subgroup that is hemodynamically distinguished by precapillary PH with elevated pulmonary vascular resistance (PVR) i.e., PAPm ≥ 25 mm Hg with normal pulmonary arterial wedge pressure (PAWP) ≤ 15 mm Hg and PVR > 3 Wood units (WU) in the absence of other causes of precapillary PH such as PH due to lung diseases, chronic thromboembolic PH (CTEPH) or other rare diseases.(1) PAH is a rare, highly debilitating and rapidly progressive condition that can lead to right heart failure and death.)2,3(The NIH registry provided the first systematic data on PAH and several studies provided data for its clinical management, reporting advances such as the introduction of PAH-specific treatment, which lead to improved outcomes.(2,4) The REVEAL registry is providing evidence in terms of outcomes and survival in PAH based on a prospective, multicentre study in